Study of T3 on the Incidence of Atrial Fibrillation in Patients Undergoing Cardiac Surgery
Phase 1
Completed
- Conditions
- Atrial Fibrillation
- Registration Number
- NCT00289367
- Lead Sponsor
- Northwell Health
- Brief Summary
The purpose of this project is to see whether treatment with a thyroid hormone, called triiodothyronine or T3, following open heart surgery reduces the risk of developing atrial fibrillation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 280
Inclusion Criteria
- Patients requiring CABG or valve repair/replacement surgery.
- Patient must be able to provide informed consent.
Read More
Exclusion Criteria
- Patients less than 18 or over 85 years of age.
- Patients less than 50kg or greater than 120kg.
- Patients currently with endocrine disorders, excluding diabetes.
- Patients currently with thyroid dysfunction (e.g., hyper- hyperthyroidism, goiter, Grave's disease), myxedema, or myxedema coma, even if treated.
- Patients currently receiving thyroid replacement therapy.
- Patients currently receiving Ketamine, levarterenol or dietary (non-food) iodine supplementation.
- Patients who have received any investigational drugs within the previous one month or five half-lives of the drug.
- Patients who are pregnant. Pregnancy testing will be done for women of child-bearing potential.
- Patients currently in atrial fibrillation.
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method incidence of atrial fibrillation during hospitalization
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
North Shore University Hospital
🇺🇸Manhasset, New York, United States